SCHEMBL17792500

SCHEMBL17792500

CC(=O)NCc1c(C)o[nH]c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRIA1 P42261 4/20 0.49
▸ GRIA3 P42263 4/20 0.49
▸ GRIA4 P48058 4/20 0.49
▸ GRIA2 P42262 3/20 0.49
▸ GRIK5 Q16478 3/20 0.49
▸ CYP1A2 P05177 3/20 0.49
▸ MEN1 O00255 3/20 0.49
▸ CYP2C9 P11712 3/20 0.49
▸ CYP2C19 P33261 3/20 0.49
▸ KMT2A Q03164 3/20 0.49
▸ MAPT P10636 2/20 0.49
▸ GRIK1 P39086 2/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ CYP2D6 P10635 2/20 0.49
▸ MAPK1 P28482 2/20 0.49
▸ TSHR P16473 1/20 0.49
▸ GRIK2 Q13002 1/20 0.49
▸ GRIK3 Q13003 1/20 0.49
▸ GRIK4 Q16099 1/20 0.49
▸ BLM P54132 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17792558 0.78 KDM4E (0.40) CYP1A2CYP2C9CYP2C19KMT2AMAPT
SCHEMBL20272577 0.69 CYP1A2 (0.59) GRIA1GRIA3GRIA4GRIA2GRIK5
SCHEMBL17792496 0.68 NPSR1 (0.33) CYP1A2CYP2C9CYP2C19KMT2AMAPT
SCHEMBL17792562 0.67 CYP1A2 (0.34) CYP1A2MEN1CYP2C9CYP2C19KMT2A
(R,S)-Ampa SCHEMBL6687427 0.66 GRIA1 (1.00) GRIA1GRIA3GRIA4GRIA2GRIK5
SCHEMBL19195013 0.66 KDM4E (0.47) CYP1A2KMT2AMAPTALDH1A1TSHR
(R,S)-Ampa SCHEMBL13957590 0.66 GRIA1 (1.00) GRIA1GRIA3GRIA4GRIA2GRIK5
SCHEMBL19194554 0.66 EZH2 (0.54) —
SCHEMBL14591562 0.66 P2RX7 (0.52) MEN1KMT2A
SCHEMBL17792537 0.65 EZH2 (0.35) CYP1A2CYP2C9CYP2C19KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9624205-B2 Substituted 6,5-fused bicyclic heteroaryl compounds Epizyme, Inc. (US) 2017-04-18 — — US disclosed
US-20160152604-A1 SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS Epizyme, Inc. 2016-06-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160152604-A1 SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP3A5, PAICS GRIA1 3797/4885GRIA3 2699/4885GRIA4 3449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback